Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease

Jeffery M. Vance; Lindsay A. Farrer; Yadong Huang; Carlos Cruchaga; Bradley T. Hyman; Margaret A. Pericak-Vance; Alison M. Goate; Michael D. Greicius; Anthony J. Griswold; Jonathan L. Haines; Julia Tcw; Gerard D. Schellenberg; Li Huei Tsai; Joachim Herz; David M. Holtzman

doi:10.1002/ana.26864

Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease

Jeffery M. Vance, Lindsay A. Farrer, Yadong Huang, Carlos Cruchaga, Bradley T. Hyman, Margaret A. Pericak-Vance, Alison M. Goate, Michael D. Greicius, Anthony J. Griswold, Jonathan L. Haines, Julia Tcw, Gerard D. Schellenberg, Li Huei Tsai, Joachim Herz, David M. Holtzman

Research output: Contribution to journal › Review article › peer-review

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024;95:625–634.

Original language	English (US)
Pages (from-to)	625-634
Number of pages	10
Journal	Annals of Neurology
Volume	95
Issue number	4
DOIs	https://doi.org/10.1002/ana.26864
State	Published - Apr 2024

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/ana.26864

Cite this

Vance, J. M., Farrer, L. A., Huang, Y., Cruchaga, C., Hyman, B. T., Pericak-Vance, M. A., Goate, A. M., Greicius, M. D., Griswold, A. J., Haines, J. L., Tcw, J., Schellenberg, G. D., Tsai, L. H., Herz, J., & Holtzman, D. M. (2024). Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease. Annals of Neurology, 95(4), 625-634. https://doi.org/10.1002/ana.26864

Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease. / Vance, Jeffery M.; Farrer, Lindsay A.; Huang, Yadong et al.
In: Annals of Neurology, Vol. 95, No. 4, 04.2024, p. 625-634.

Research output: Contribution to journal › Review article › peer-review

Vance, JM, Farrer, LA, Huang, Y, Cruchaga, C, Hyman, BT, Pericak-Vance, MA, Goate, AM, Greicius, MD, Griswold, AJ, Haines, JL, Tcw, J, Schellenberg, GD, Tsai, LH, Herz, J & Holtzman, DM 2024, 'Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease', Annals of Neurology, vol. 95, no. 4, pp. 625-634. https://doi.org/10.1002/ana.26864

@article{8d7c2c86fd634d09a4c5519c929ac6b6,

title = "Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease",

abstract = "Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024;95:625–634.",

author = "Vance, {Jeffery M.} and Farrer, {Lindsay A.} and Yadong Huang and Carlos Cruchaga and Hyman, {Bradley T.} and Pericak-Vance, {Margaret A.} and Goate, {Alison M.} and Greicius, {Michael D.} and Griswold, {Anthony J.} and Haines, {Jonathan L.} and Julia Tcw and Schellenberg, {Gerard D.} and Tsai, {Li Huei} and Joachim Herz and Holtzman, {David M.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.",

year = "2024",

month = apr,

doi = "10.1002/ana.26864",

language = "English (US)",

volume = "95",

pages = "625--634",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group

T2 - Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease

AU - Vance, Jeffery M.

AU - Farrer, Lindsay A.

AU - Huang, Yadong

AU - Cruchaga, Carlos

AU - Hyman, Bradley T.

AU - Pericak-Vance, Margaret A.

AU - Goate, Alison M.

AU - Greicius, Michael D.

AU - Griswold, Anthony J.

AU - Haines, Jonathan L.

AU - Tcw, Julia

AU - Schellenberg, Gerard D.

AU - Tsai, Li Huei

AU - Herz, Joachim

AU - Holtzman, David M.

PY - 2024/4

Y1 - 2024/4

N2 - Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024;95:625–634.

AB - Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024;95:625–634.

UR - http://www.scopus.com/inward/record.url?scp=85181509496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85181509496&partnerID=8YFLogxK

U2 - 10.1002/ana.26864

DO - 10.1002/ana.26864

M3 - Review article

C2 - 38180638

AN - SCOPUS:85181509496

SN - 0364-5134

VL - 95

SP - 625

EP - 634

JO - Annals of Neurology

JF - Annals of Neurology

IS - 4

ER -

Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this